MRNA

The company aims to test 10,000 personalized mRNA therapies, including cancer vaccines, between September 2023 to the end of the decade.

Damar Hamlin’s collapse on Monday Night Football calls attention to a medical myth that will not die.

Scientist Dr. Robert Malone went viral on Twitter after he claimed that a teacher was fired for giving students an extra credit assignment involving Joe Rogan.

Afrigen is the linchpin of global project to use mRNA technology to empower low-resource countries to make their own vaccines against killer diseases from TB to HIV. What will it take to succeed?

Gov. Ron Desantis has asked Florida's supreme court to impanel a grand jury to investigate COVID-19 vaccine makers.

The country's intensifying efforts to boost vaccination rates and expand hospital capacity stop short of approving foreign vaccines.

BioNTech's mRNA cancer trials started long before the pandemic, and have shown some early encouraging signals.

The newest medical innovation to fight COVID-19 is here, but people are hardly racing to get it this time around. The Pfizer and Moderna bivalent booster shots have been available in Michigan since early September. The vaccine includes mRNA components of the original COVID-19 strain (like the initial vaccines) plus components of the omicron BA.4 and BA.5 subvariants to help fight the latest strains of the virus.

Moderna has announced plans to file a lawsuit against rival vaccine developer Pfizer and its partner, BioNTech, claiming patent infringement related to the company’s mRNA COVID vaccine. Moderna said it pioneered and patented its mRNA technology for therapeutics and vaccines between 2010 and 2016, and that Pfizer copied the technology without permission to make its COVID vaccine. The U.S. has administered more than 360 million doses of Pfizer’s COVID vaccine as of late August. That’s compared to more than 229 million doses of Moderna’s shot, and almost 18.9 million doses of the Johnson & Johnson vaccine, according to CDC data. In Michigan, more than 6.9 million doses of Pfizer’s vaccine have been administered in Michigan, compared to more than 4.3 million doses of Moderna’s shot.

The lawsuit sets up clash between rival vaccine makers who used novel mRNA technology to speed delivery of shots.

Americans are one step closer to securing a COVID-19 vaccine booster that better targets newer variants. Pfizer and partner BioNTech have requested emergency use authorization for their omicron-specific bivalent vaccine, which contains mRNA coding for both the original SARS-CoV-2 spike protein and the BA.4/BA.5 omicron subvariant. More than 6.3 million Michigan residents have gotten at least one dose of COVID vaccine since late 2020, or about 63.2% of the population. Much like the primary shots, older populations have been more likely to get a booster than younger generations. Almost 7 million doses of Pfizer’s vaccines have gone into arms in Michigan to date, compared to about 4.3 million doses of Moderna’s vaccine, 395,812 doses of the Johnson & Johnson vaccine, and 130 doses of the Novavax vaccine.

The Novavax vaccine, a more traditional type that does not use mRNA technology to fight COVID-19, is now available in Michigan. Some pharmacies and federally qualified health centers had the vaccine earlier because they received the vaccine through federal channels, Wuth reported. As of last week, when the state’s vaccine dashboard was last updated, about 80 people had received a dose of the Novavax vaccine in Michigan. Pfizer’s vaccine, first approved in late 2020, is the most administered vaccine in Michigan, where about 58% of residents are fully vaccinated against COVID-19. Most commonly reported side effects of the Novavax vaccine were fatigue, muscle pain, headache, joint pain, nausea and fever.

U.S. regulators have granted emergency use authorization for a new COVID-19 vaccine developed by Novavax. Dr. Monica Gandhi, an infectious disease specialist and a professor of medicine at the University of California, San Francisco, explains what sets this new vaccine apart from the Pfizer-BioNTech and Moderna shots and how it could combat future variants.

How Sotiris Missailidis, head of R&D in Brazil's vaccine agency, used the COVID crisis to push through a game-changing effort for middle-income countries to invent their own mRNA vaccine.

Novavax's new Covid vaccine is perfect for people scared of mRNA tech. Here's why experts say many of them still won't take it.

Pfizer and Moderna have refused to divulge details of how to make their cutting-edge COVID shots. Here's what two scientists — and longtime best friends — are doing about it.

Florida Gov. Ron DeSantis said the Biden administration is lying about his state ordering COVID vaccines for young children, and the media played along

The UK’s mix-and-match approach to vaccinations looks accidentally brilliant.

China is trying to navigate its biggest coronavirus outbreak without a tool it could have adopted many months ago, the kind of vaccines that have proven to offer the best protection against the worst outcomes from COVID-19.

China is trying to navigate its biggest coronavirus outbreak without a tool it could have adopted many months ago, the kind of vaccines that have proven to offer the best protection against the worst outcomes from COVID-19. As early as the spring of 2020 a Chinese pharmaceutical company, Fosun Pharma, reached an agreement to distribute — and eventually manufacture — the mRNA vaccine made by Pfizer and BioNTech. It still has not been cleared in mainland China, despite being authorized for use by separate authorities in Hong Kong and Macao.

The biotech Arcturus has shown how new self-copying mRNA technology could get many people vaccinated quickly.

Unlike previously used viral vector vaccines, mRNA vaccines don’t introduce live or dead virus into the body as a means of triggering antibody production. “mRNA vaccine technology for treating diseases isn’t going anywhere. “It’s a totally different ball game.”Research into mRNA technology for vaccines goes back decades, though the efforts improved within the last 10 years. “Every pharma company now is investing billions of dollars into developing these mRNA vaccines into the anti-cancer medicine,” Walter said. While no mRNA vaccine for cancer has gained approval from the U.S. Food and Drug Administration, there’s hope that the success of COVID-19 vaccines will help accelerate clinical research.

Stories about the continuing risks of the pandemic may create unintended harms.

mRNA-based medicine has been a decade in the making.

The FDA and CDC offered little guidance about who should get the newly authorized second COVID-19 booster shot. We break it down.

China will require mass distribution of an existing mRNA booster shot along with antivirals to adapt.

A new study found that COVID-19 can increase the risk for developing 20 cardiac problems, including stroke and heart attack. Dr. Tara Narula reports.

Indonesia hit a daily record high of more than 64,000 cases last week, superseding daily infections in the previous wave which peaked just under 57,000 in July.

Egypt, Kenya, Nigeria, Senegal, South Africa and Tunisia will be the first African countries to receive the technology required to produce mRNA vaccines on the continent

European Union leaders have lauded the bloc’s cooperation with Africa on vaccines in the fight against the coronavirus, but there is no sign they will move toward the temporary lifting of intellectual property rights protection for COVID-19 shots

A new study says a million lives could be saved if mRNA vaccines went to poorer countries.

Current trials are underway to use mRNA in fighting multiple different cancers.

Current trials are underway to use mRNA in fighting multiple different cancers.

Moderna applied for emergency approval of its Covid vaccine for 12- to 17-year-olds in June, but the FDA said its review wouldn't be completed before January.

Added benefits of booster doses were especially prominent among people 50 to 64 and those 65 and older, a second study looking at data from April to late December found. This is consistent with recent information from some Michigan health systems, reporting 85 to 95% of patients with COVID-19 have not had booster shots. About 95% of vaccinated patients with COVID-19 admitted to Southfield-based Beaumont Health’s eight hospitals have not received booster shots, Dr. Matthew Sims, director of infectious disease research, said Friday. In Michigan, about 47% of people who are fully vaccinated have gotten booster shots. Before omicron, only those at greater risk of severe outcomes were told they should receive booster shots.

Hospitals are now tracking the percentage of their COVID-19 patients who have received booster shots of the COVID-19 vaccine, and the rates are low, about 5 to 15% at some reporting health systems. Of those 33, five had received booster shots, Dr. Christine Nefcy, chief medical officer, said during a Tuesday COVID update. Of them, 51 were vaccinated and 17, about 14%, had received their primary doses and a booster. “The numbers strongly, strongly support this.”People with booster shots see decreased illness, decreased hospitalizations and, certainly, decreased deaths, he said. In Michigan, about 47% of people who are fully vaccinated have gotten booster shots.

In September 2020, regulators asked for extra safety data on the new mRNA vaccines. The human cost of that request is far from clear.

The Maryland company's vaccine will be the fifth available in South Korea, where 84 percent of the public is fully vaccinated.

While the vaccine-making technology has had impressive results, new shots that are simpler to make and easier to store may hold the key to ending the global pandemic.

Almost 17 million Americans have received the Johnson & Johnson COVID-19 vaccine, a huge number that seems to have been forgotten. Here is what to know now.

Health experts expect to see more “flurona” as flu cases rise and coronavirus cases continue to surge due to the omicron variant.

Researchers are looking at ways messenger RNA technology from COVID-19 vaccines can be used to fight other illnesses and diseases.

These are the stocks posting the largest moves before the bell.

Modern described the findings as reassuring, but said it will also continue to develop an omicron-specific booster candidate.

We still don’t how many shots we really need, or how often we’ll need them.

Almost all the vaccines in a study of seven different shots appeared to boost the immune response when used as a third dose.

Covid-19 booster shots are being rolled out in the U.S. and other countries in response to waning antibody levels in already vaccinated individuals, and the increased threat posed by the hyper-infectious delta variant of the coronavirus that causes the disease. Giving a third shot to healthy people is a contentious strategy, since many low- and middle-income countries have yet to immunize even a 10th of their population. From a scientific standpoint, though, there’s mounting evidence that it cou

The Biden administration's new vaccine mandate for businesses with at least 100 employees will kick in on January 4, but these six myths are still holding people back from getting vaccinated.

It’s possible that a good deal of the difference in the COVID vaccines’ performance can be summed up with a simple phrase: More is better.

Senegal and Rwanda have signed an agreement with German company BioNTech for the construction of its first start-to-finish factories to make messenger RNA vaccines in Africa.

KALAMAZOO, MI — The Kalamazoo County Health & Community Services Department is now offering booster doses from Moderna and Jonson & Johnson, the department announced on Monday, Oct. 25. COVID-19 vaccines continue to be widely available from local providers and pharmacies. The health department recommends people use www.vaccines.gov to find a vaccination location. Those eligible for a booster may choose which vaccine they receive as a booster dose. For questions about which booster to receive, the health department recommends speaking with your own health care provider for advice.

Covid-19 booster shots are being rolled out in the U.S. and other countries in response to waning antibody levels in already vaccinated individuals, and the increased threat posed by the hyper-infectious delta variant of the coronavirus that causes the disease. Giving a third shot to healthy people is a contentious strategy, since many low- and middle-income countries have yet to immunize even a 10th of their population. From a scientific standpoint, though, there’s mounting evidence that it cou

A CDC advisory group voted unanimously to allow immunocompromised people to get a third dose of a COVID-19 vaccine.

Pharmaceutical company BioNTech says it wants to use the mRNA technology behind its coronavirus vaccine to target malaria.

The Johnson and Johnson COVID vaccine may not be as effective as vaccines that use mRNA technology (Pfizer and Moderna), according to a new study.

A new study has found that some vaccines may offer COVID-19 immunity for years, especially for those who contracted and recovered from the virus before immunization.

The CDC’s vaccine advisory panel said that rate reports of heart inflammation in younger people likely are associated with the mRNA vaccines.

The world’s leading COVID-19 vaccines may offer lasting protection that diminishes the need for frequent booster shots.

In a rare acknowledgement, China’s top disease control official says current vaccines offer low protection against the coronavirus and mixing them is among strategies being considered to boost their effectiveness.

(AP Photo/Michael Sohn, FILE)Moderna Inc. announced Tuesday it has started testing its mRNA-1273 vaccine candidate against COVID-19 in children ages 6 months to less than 12 years old. This is part of Moderna’s Phase 2/3 vaccine study called “KidCOVE” in which is intends to enroll about 6,750 pediatric participants in theU.S. Such trials in children already were underway in children aged 12 to 15. Both Pfizer and Moderna have started these trials and expect to have results from their trials in older children this summer. A vaccine for younger children has not been expected ready until early next year (2022).

The Food and Drug Administration advisory panel unanimously voted Friday afternoon to recommend the Johnson & Johnson’s COVID-19 vaccine for an emergency use authorization. For eight hours, the group of independent experts had reviewed the safety and efficacy of the vaccine. READ: FDA finds Johnson & Johnson vaccine effectively prevents COVIDWhile the Johnson & Johnson vaccine is less effective than Pfizer and Moderna’s vaccines, the experts noted that no one who received the Johnson & Johnson vaccine was hospitalized or died from coronavirus. READ: Here’s what makes J&J vaccine different than the othersAdStudies in children are planned with the older group of children expected to begin receiving the vaccine as soon as early March. There are also additional studies planned in immunocompromised people.

The data that Johnson & Johnson submitted to the Food and Drug Administration for its emergency use authorization was made public Wednesday.

Here’s what to know about the J&J vaccine:The J&J vaccine can be stored in a normal refrigerator unlike the Pfizer and Moderna vaccines -- it’s not a mRNA vaccine. Testing, efficacyThe Johnson & Johnson vaccine has been tested on nearly 44,000 people in United States, Latin America and South Africa. Henry Ford Hospital in Detroit also was one of the clinical sites for the J&J vaccine, so many Metro Detroiters have already received the vaccine. Johnson & Johnson is running an additional trial to test effectiveness of a second dose of its vaccine. AdFeb. 24: FDA says J&J 1-dose shot prevents COVID; final decision soonFeb. 4: Johnson & Johnson asks US regulators to OK its one-shot COVID-19 vaccineMore: Local 4′s Dr. Frank McGeorge answers COVID vaccine questions

DETROIT – Since the coronavirus pandemic began, Dr. Frank McGeorge has been keeping viewers up-to-date and informed on all fronts. You should get the vaccine as close to 21 days after for the Pfizer vaccine and 28 days for the Moderna. The recommendation is to wait at least 14 days between any other vaccine and the COVID-19 vaccine. If you had significant side effects with the first dose you’ll likely have a fever with the second dose. RELATED: Tracking Michigan COVID-19 vaccine dataQuestions about coronavirus?

DETROIT – Making enough COVID-19 vaccine doses for the entire world could take years due to manufacturing challenges. They’re incredibly small, and critical to the COVID-19 vaccine rollout -- and there aren’t nearly enough of them. Whenever we reach out to our companies to ask them whether they could support manufacturing of the lipid components. For example, as soon as they hear it’s to support a COVID-19 vaccine, you know, they’re completely engaged.”Alliances are being forged in the private sector. Greenlight Biosciences, a biotech firm in Boston, has delayed the development of their mRNA vaccine candidate so they can tailor it to the newer variants of coronavirus.

Due to limited quantities of and high demand for a COVID-19 vaccine, states are planning to administer the vaccinations in multiple phases, prioritizing individuals who are at greater risk. The U.S. Food and Drug Administration (FDA) has authorized widespread use of both Pfizer’s COVID vaccine and Moderna’s COVID vaccine. MDHHS officials say that it is estimated that COVID-19 vaccines will be available to everyone who is recommended to receive it by late spring of 2021. Michigan health officials are hoping to vaccinate 70 percent of residents over the age of 18 years by the end of 2021. Initially, five Michigan hospitals would be the first to get the vaccine, according to the Michigan Health and Hospital Association.

Michigan healths officials offered an update Friday afternoon about distribution of the COVID-19 vaccine, priority groups for vaccination and efficacy and safety information currently available. Dr. Joneigh Khaldun, chief medical executive and chief deputy for health, Michigan Department of Health and Human Services (MDHHS), and Robert Swanson, MDHHS Division of Immunizations director, hosted Friday’s event. On Thursday, the Food and Drug Administration (FDA) vaccine advisory panel recommended the Pfizer COVID-19 vaccine needs to be granted an emergency use authorization. Initially, five Michigan hospitals would be the first to get the vaccine, according to the Michigan Health and Hospital Association. it’s estimated that over a period of weeks the mRNA is naturally destroyed after it has been used to produce spike proteins.

Questions about the vaccine scienceMany people have questions about the two vaccines closest to approval. Will the benefit outweigh the risk in this case?”Both the Pfizer and the Moderna vaccines are mRNA vaccines, meaning they are not live virus vaccines. it’s estimated that over a period of weeks the mRNA is naturally destroyed after it has been used to produce spike proteins. Should you get an antibody test to determine your ranking for the vaccine? Another related question is if you should get an antibody test to help determine your ranking for receiving the vaccine?

How could scientists race out COVID-19 vaccines so fast without cutting corners? A head start helped -- over a decade of behind-the-scenes research that had new vaccine technology poised for a challenge just as the coronavirus erupted. Both shots -- one made by Pfizer and BioNTech, the other by Moderna and the National Institutes of Health -- are so-called messenger RNA, or mRNA, vaccines, a brand-new technology. U.S. regulators are set to decide this month whether to allow emergency use, paving the way for rationed shots that will start with health workers and nursing home residents. Traditionally, making vaccines required growing viruses or pieces of viruses — often in giant vats of cells or, like most flu shots, in chicken eggs — and then purifying them before next steps in brewing shots.

DETROIT The first group of volunteers in Michigan to participate in the Moderna COVID-19 vaccine study received their first shots Wednesday, Henry Ford Health System announced. Henry Ford Health System is the only hospital in Michigan selected as a trial site for phase three of the Moderna mRNA-1273 Coronavirus Efficacy (COVE) vaccine study. This is a historic moment, said Dr. Marcus Zervos, division chief of Infectious Disease for Henry Ford Health System. I give them all the respect in the world.The first dose of the Moderna COVID-19 vaccine study in Michigan was administered Wednesday, Aug. 5, 2020. About 90 healthcare systems across the United States are working competitively to enroll a total of 30,000 volunteers to participate in the Moderna vaccine study.